Overview

• Treace Medical Q3 revenue grows 11% yr/yr, slightly beating analyst expectations

• The bunion correction implants maker reports Q3 net loss of $16.3 mln, adjusted EBITDA improves by 49%

• Treace revises full-year 2025 revenue guidance downward due to shifting surgeon preferences

Outlook

• Treace revises 2025 revenue guidance to $211 mln-$213 mln, down from $224 mln-$230 mln

• Company expects 2025 Adjusted EBITDA loss of $6.5 mln-$7.5 mln, previously breakeven

• Treace cites lower Lapiplasty sales due to surgeon preference shift and macroeconomic factors

Result Drivers

• MARKET PENETRATION - Revenue growth driven by greater market penetration and expanded portfolio of solutions, per CEO John T. Treace

• MINIMALLY INVASIVE SHIFT - Lapiplasty volumes impacted by shift in surgeon and patient preferences towards minimally invasive solutions, per CEO John T. Treace

• MACROECONOMIC HEADWINDS - Broader macroeconomic conditions and softer consumer sentiment leading to deferrals of elective bunion procedures, per CEO John T. Treace

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Treace Medical Concepts Inc is $7.00, about 10.7% above its November 5 closing price of $6.25

Press Release: ID:nGNX3pHpcM

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)